Table 3.
Patient reported outcomes among MED and MEDREC participants by daily use frequency
| MED (n = 531) | MEDREC (n = 458) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subgroup | Light n=200 (38%) | Moderate n=197 (37%) | Heavy n=134 (25%) | F | P | Light n=107 (23%) | Moderate n=185 (40%) | Heavy n=166 (36%) | F | P |
| Pain severity | 5.4 ± 0.2 n=186 |
6.2 ± 0.2 n=190 |
6.2 ± 0.2 n=127 |
9.1 | <0.0001ab | 5.2 ± 0.2 n=102 |
5.0 ± 0.2 n=170 |
5.0 ± 0.2 n=156 |
0.3 | 0.76 |
| Pain interference | 4.43 ± 0.2 n=185 |
5.44 ± 0.2 n=190 |
5.5 ± 0.2 n=127 |
7.8 | <0.0001ab | 3.9 ± 0.3 n=102 |
3.8 ± 0.2 n=170 |
3.9 ± 0.22 n=156 |
0.1 | 0.87 |
| Physical Function | 39.0 ± 0.2 n=179 |
39.2 ± 0.2 n=187 |
39.4 ± 0.2 n=126 |
1.0 | 0.372 | 37.8 ± 0.2 n=100 |
38.7 ± 0.2 n=162 |
38.4 ± 0.2 n=152 |
3.5 | 0.03a |
| Sleep Disturbance | 51.3 ± 0.6 n=179 |
51.9 ± 0.63 n=187 |
52.7 ± 0.7 n=126 |
0.9 | 0.41 | 48.5 ± 0.8 n=101 |
49.3 ± 0.7 n=162 |
50.1 ± 0.7 n=153 |
1.2 | 0.31 |
| Fatigue | 54.5 ± 1.1 n=180 |
56 ± 1.1 n=189 |
55.2 ± 1.3 n=126 |
0.5 | 0.617 | 49.9 ± 1.2 n=101 |
51.8 ± 1.0 n=166 |
51.27 ± 1.0 n=153 |
0.8 | 0.45 |
| Depression | 5.9 ± 0.4 n=182 |
6.7 ± 0.4 n=190 |
7.5 ± 0.5 n=127 |
2.7 | 0.067 | 5.8 ± 0.6 n=102 |
5.6 ± 0.4 n=167 |
5.7 ± 0.4 n=155 |
0.0 | 0.95 |
| Anxiety | 5.6 ± 0.43 n=174 |
6.3 ± 0.4 n=179 |
7.18 ± 0.50 n=124 |
2.8 | 0.059 | 5.4 ± 0.5 n=98 |
5.9 ± 0.4 n=157 |
5.3 ± 0.4 n=149 |
0.6 | 0.55 |
| Cognitive function | 37.2 ± 0.8 n=174 |
35.0 ± 0.8 n=180 |
34.9 ± 0.9 n=123 |
2.6 | 0.071 | 37.0 ± 0.9 n=95 |
38.2 ± 0.7 n=151 |
38.0 ± 0.7 n=147 |
0.6 | 0.54 |
| Positive Affect | 23.5 ± 0.4 n=176 |
24.6 ± 0.4 n=181 |
25.2 ± 0.5 n=124 |
3.3 | 0.037b | 24.6 ± 0.6 n=98 |
25.0 ± 0.5 n=158 |
25.2 ± 0.5 n=151 |
0.3 | 0.71 |
| Negative Affect | 24.7 ± 0.5 n=176 |
26.1 ± 0.4 n=181 |
26.8 ± 0.6 n=125 |
4.5 | 0.011b | 25.9 ± 0.6 n=97 |
25.9 ± 0.5 n=158 |
26.7 ± 0.5 n=151 |
0.9 | 0.40 |
Table 3. Light = 1-2 uses per day, Moderate = 3-4 uses per day, Heavy =5 or more uses per day. Values represent estimated marginal mean ± standard error (SE). Adjusted for age, sex, and opioid and benzodiazepine. Post hoc pairwise differences obtained using Bonferroni’s test with paired differences in marginal means labeled a: light < moderate, b: light < heavy. Tests are two-tailed and significance considered p < 0.05. Significant p values are bold.